Join to view full profile
201 North Broadway StreetViragh BLDG 5th FLBaltimore, MD 21287
Phone+1 410-955-8964
Fax+1 410-367-2194
Dr. Azad is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
Baylor College of MedicineResidency, Internal Medicine, 2001 - 2004- Baylor College of MedicineClass of 2001
Certifications & Licensure
MD State Medical License 2008 - 2028
PA State Medical License 2004 - 2026
VA State Medical License 2005 - 2026
NC State Medical License 2020 - 2022
DC State Medical License 2013 - 2016
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2017
Clinical Trials
- Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies
- Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer Start of enrollment: 2011 Jan 01
- A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma
Publications & Presentations
PubMed
- Clinical, genomic, and spatial transcriptomic features of pancreatic adenosquamous carcinoma support subtype-specific therapeutic strategies.S Daniel Haldar, Meredith Wetzel, Jiayun Lu, Jae W Lee, Hassan Sinan
Clinical Cancer Research. 2026-08-14 - Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial.Eric S Christenson, Jeremiah A Wala, Rose Parkinson, Natalie B Collins, Christopher Jakubowski
Nature Communications. 2026-07-23 - Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.Eileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, Mitesh J Borad, Filippo Pietrantonio
The New England Journal of Medicine. 2026-07-23
Lectures
- What Is Working in Clinical Trial Recruitment? - Panel ModeratorASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
- ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Drug Combination Prompts Immune Response in Some Resistant Pancreatic CancersNovember 15th, 2024- Drug Combination Boosts Immune Response in Resistant Pancreatic CancersNovember 15th, 2024
- Drug Combination Prompts Immune Response in Some Resistant Pancreatic CancersNovember 14th, 2024
Grant Support
- Optimization of an active mutant KRAS peptide vaccine in colorectal cancerJOHNS HOPKINS UNIVERSITY2025–2029
- Optimization of an active mutant KRAS peptide vaccine in colorectal cancerJOHNS HOPKINS UNIVERSITY2025–2029
- Optimization of an active mutant KRAS peptide vaccine in colorectal cancerJOHNS HOPKINS UNIVERSITY2025–2029
- Molecular Targets for Cancer Detection and TreatmentJOHNS HOPKINS UNIVERSITY1979–2027
Committees
- Member, Committee on Appropriateness Criteria, Expert Panel on Interventional Radiology, American College of Radiology 2015 - Present
Other Languages
- Urdu, Hindi
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/nilofer-azad
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
